Riskpilot← Back to searchSign inGet full accessAlexion Pharma Nordics AB
ABActiveOrg 5568391022Solnavägen 3Activities of agents involved in the wholesale of other particular products · NACE 4618Est. 201116 employees
Revenue 2024
SEK 65M
-76% vs 2023
EBITDA margin
7.2%
-62% vs 2023
Equity ratio
30.5%
Financial strength
Net profit 2024
SEK 4,5M
-54% vs 2023
| Revenue | SEK 65M | -76% |
| EBITDA | SEK 4,7M | -62% |
| Net profit | SEK 4,5M | -54% |
| Total assets | SEK 94,9M | -46% |
| Equity | SEK 29M | -47% |
| Employees | 16 | — |
Legal name
Alexion Pharma Nordics AB
Org number
5568391022
Legal form
Aktiebolag
NACE code
4618 · Activities of agents involved in the wholesale of other particular products
Founded
20 januari 2011
Share capital
SEK 50 000
Employees
16 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska bedriva: 1. Direkt eller indirekt, i Sverige och utomlands, kommersialisera produkter för behandling av humanpatienter (olika typer av medicin samt övriga generella hälsoprodukter). 2. Direkt eller indirekt distribuering, marknadsföring och säkerhetsövervakning av verksamhet hänförlig till terapeutiska produkter angivna i 1. 3. Att registrera, ansöka om, eller medansöka om, köp eller övrigt förvärv, och skydda, förlänga och förnya, samt mer generellt använda immateriella rättigheter, licenser, varumärken, tillstånd för marknadsföring och andra licenser nödvändiga för utförandet av tjänsterna angivna i 1 och 2. Övrig verksamhet förenlig med ovan angivna tjänster.
Address
Solnavägen 3
Phone
+46855772750
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 228 551 | 234 166 | 261 559 | 269 323 | 65 047 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 10 393 | 9 923 | 7 278 | 12 327 | 4 696 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 10 393 | 9 923 | 7 278 | 12 327 | 4 696 |
| Net financials | 9 | −173 | 513 | 134 | 1 661 |
| Profit before tax | 10 402 | 9 749 | 7 791 | 12 461 | 6 357 |
| Tax | −3 703 | −4 164 | −1 887 | −2 668 | −1 837 |
| Net profit | 6 699 | 5 585 | 5 904 | 9 793 | 4 520 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 60 650 | 92 274 | 107 642 | 176 522 | 94 921 |
| Equity | 33 020 | 39 347 | 45 919 | 54 629 | 28 984 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 27 629 | 52 926 | 61 723 | 121 892 | 65 937 |
| Total debt | 27 629 | 52 926 | 61 723 | 121 892 | 65 937 |
EBITDA margin
7.2%
This company
15.8%
Market median
-54% vs market
20202024
Equity ratio
30.5%
This company
38.2%
Market median
+20% vs market
20202024
Return on equity
15.6%
This company
18.4%
Market median
+15% vs market
20202024
Net profit margin
6.9%
This company
8.1%
Market median
-15% vs market
20202024
Asset turnover
0.69×
This company
1.12×
Market median
-38% vs market
20202024
Debt / equity
2.27×
This company
0.62×
Market median
-266% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SI Chief Auditor | Chief Auditor | 2025 |
| Former (3) | ||
LP Chief Auditor | Chief Auditor | 2022 – 2022 |
EM Authorized Recipient of Service | Authorized Recipient of Service | 2022 – 2023 |
JR Chief Auditor | Chief Auditor | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2026 | |
| Chairman | 2025 | |
| Board of Directors | 2021 | |
| Former (9) | ||
| Chairman | 2025 – 2025 | |
| Chairman | 2021 – 2025 | |
| Chairman | 2022 – 2023 | |
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2022 – 2023 | |
| Chairman | 2020 – 2021 | |
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2021 – 2021 | |
| Board of Directors | 2024 – 2026 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ALEXION HOLDING B.V.
Alexion Pharma Nordics AB (this company)Board members of Alexion Pharma Nordics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Pontus Söderlind | Chief Auditor | 0 companies |
| Emma Maria Johanna Sjögren | Authorized Recipient of Service | 0 companies |
| Sebastian Ionescu | Chief Auditor | 0 companies |
| John Robert Nyholm | Chief Auditor | 0 companies |
| Anna Maria Andersson | Board of Directors | 0 companies |
| Adrian Esteban Cuadra León | Chairman | 0 companies |
| Hans Jacob Julius Brun | Chairman | 0 companies |
| Hans Fredrik Juserius | Chairman | 0 companies |
| Bettina Nauli | Chairman | 0 companies |
| Jonas Fredrik Norlander | Board of Directors | 0 companies |
| Lars Graham Skarnvad | Board of Directors | 0 companies |
| Lars Graham Skarnvad | Chairman | 0 companies |
| Vivien Ruth Greer | Board of Directors | 0 companies |
| Jan Gustav Tollemar | Board of Directors | 0 companies |
| Karl Johan Georg Myrén | Board of Directors | 0 companies |
| Ziba Zareie | Board of Directors | 0 companies |